1Dworakowska D, Gozdz S, Jassem E, et al. Prognostic relevance of proliferating cell nuclear antigen and p53 expression in non-small cell lung cancer. Lung Cancer, 2002, 35(1): 35-41.
2Tanaka F, Yanagihara K, Otake Y, et al. Prognostic factors in patients with resected pathologic (p-) T1-2N 1MO non-small cell lung cancer(NSCLC). Eur J Cardiothorac Surg, 2001, 19(5): 555-561.
3Naruke T, Tsuchiya R, Kondo H, et al. Lymph node sampling in lung cancer:, how should it be done? Eur J Cardiothorac Surg, 1999, 16Suppl(1 ):S 17-24.
4Tammemagi MC, McLaughlin JR, Mullen JB, et al. A study of smoking, p53 tumor suppressor gene alterations and non-small cell lung cancer. Ann Epidemiol, 2000, 10(3): 176-185.
5Niklinska W, Chyczewski L, Laudanski J, et al. Detection of p53 abnormalities in non-small cell lung cancer by yeast functional assay.Folia Histochem Cytobiol, 2001, 39(2): 147-148.
5Boldrini L,Faviana P,Gisfredi S,et al.Identification of FAS(APO-1/CD95)and p53 gene mutations in non-small cell lung cancer[J].Int J Oncol,2002,20(1):155-159.
6Dash PR,Read ML,Barrett LB,et al.Factors affecting blood clearance and in vivo distribution of polyelectrolyte complexes for gene delivery[J].Gene Ther,1999,6(4):643-650.
7Takayama K,Nakanishi Y,Hara N.Gene therapy for lung cancer treatment[J].Nippon Rinsho,2000,58(2):1048-1052.
8Lieberman DA,Hoffman B,Steinman RA.Molecular control of growth arrest and apoptosis:p53-dependent and independent pathways[J].Oncogene,1995,11(1):199-210.
9Levine AJ.p53,the cellular gatekeeper for growth and division[J].Cell,1997,88(3):323-331.
10Fox JL.Gene therapy safety issues come to fore[J].Nat Biotech,1999,17(12):1153.
